Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific ...

New research reveals a strong link between eye health and overall well-being and if you take regular eye check ups, it can ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across ...

Retinal microvascular changes detected by OCT-A may provide details for earlier diagnosis of coronary artery stenosis.

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication ...

Retinal damage caused by diabetes and mild cognitive impairment may predict the development of Alzheimer disease.

Retinal scans, aided by artificial intelligence (AI), may soon offer doctors a simple, non-invasive way to detect several ...